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The transcription factor FOXP3 plays key roles in the development and function of 
regulatory T cells (Treg) capable of preventing and correcting immunopathology. There 
has been much interest in exploiting Treg as adoptive cell therapy in man, but issues of 
lack of nominal antigen-specificity and stability of FoxP3 expression in the face of pro-
inflammatory cytokines have been a concern. In order to enable fundamental studies of 
human FOXP3 (hFOXP3) gene regulation and to provide preclinical tools to guide the 
selection of drugs that might modulate hFOXP3 expression for therapeutic purposes, 
we generated hFOXP3/AmCyan bacterial artificial chromosome (BAC) transgenic mice 
and transfectants, wherein hFOXP3 expression was read out as AmCyan expression. 
Using the transgenic mice, one can now investigate hFOXP3 gene expression under 
defined experimental conditions used for mouse Foxp3 (mFoxp3) studies. Here, we 
demonstrate that hFOXP3 gene expression in BAC transgenic mice is solely restricted 
to CD4+ T-cells, as for mFoxp3 gene expression, showing that hFOXP3 expression in 
Treg cells depends on fundamentally similar processes to mFoxp3 expression in these 
cells. Similarly, hFOXP3 expression could be observed in mouse T-cells through TCR 
stimulation in the presence of TGF-β. These data suggest that, at least in part, cell type-
specific human and mouse foxp3 gene expression is regulated by common regulatory 
regions which for the human, are located within the 110-kb human FOXP3 BAC DNA. 
To investigate hFOXP3 gene expression further and to screen potential therapeutics 
in modulating hFOXP3 gene expression in vitro, we also generated hFOXP3/AmCyan 
expression reporter cell lines. Using the reporter cells and transcription factor inhibitors, 
we showed that, just as for mFoxp3 expression, inhibitors of NF-κB, AP1, STAT5, 
Smad3, and NFAT also block hFOXP3 expression. hFOXP3 induction in the reporter 
cells was also TGF-β dependent, and substantially enhanced by an mTOR inhibitor, 
Torin1. In both the reporter transgenic mice and cell lines, histone H4 molecules in the 
hFOXP3 promoter and enhancers located in human CNS1 and CNS2 regions were 
highly acetylated in natural Treg and TCR/TGF-β-induced Treg, indicating hFOXP3 gene 
expression is regulated by mechanisms similar to those previously identified for the 
mFoxp3 gene.
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inTrODUcTiOn
Regulatory T  cells (Treg) are essential for preventing autoim-
mune disease and other forms of immunopathology (1–3). 
Their development and function is regulated by a transcription 
factor Foxp3 (1, 4). Due to the availability of genetically modi-
fied/disease-model mice, major efforts investigating foxp3 gene 
expression have been conducted in mice. However, recent studies 
have suggested that mouse and human foxp3 genes might be sub-
ject to different regulatory mechanisms (5–14), suggesting that 
mouse data may not necessarily guide clinical relevance. There 
has been much interest in exploiting natural or thymic-derived 
regulatory T-cells (nTreg or tTreg) as adoptive cell therapy in 
man, but issues of antigen-specificity and stability of FoxP3 
expression in the face of pro-inflammatory cytokines have been 
a concern (15, 16). As antigen-specific CD4+ Foxp3+ Treg can 
be induced in vitro (iTreg), it has also been considered desirable 
to acquire expanded, stable antigen-specific populations of Treg, 
as efficient mediators of suppression (15, 17). So as to enable 
further fundamental studies of hFOXP3 gene regulation, and 
to provide preclinical tools to guide the selection of drugs that 
might modulate hFOXP3 expression for therapeutic purposes, 
we generated hFOXP3/AmCyan bacterial artificial chromosome 
(BAC) transgenic mice as well as transfectants into a murine 
T-cell line, wherein hFOXP3 expression could be investigated 
through AmCyan expression.
Mouse Foxp3 (mFoxp3) gene expression is regulated 
by TCR signaling, IL-2, and TGF-β through at least four 
distinct regions, a promoter and elements located in three 
CNSs (conserved non-coding sequence), CNS1, CNS2, and 
CNS3 (18–30). The mFoxp3 promoter is located upstream of 
the non-coding exon, and its activity is regulated by several 
transcription factors activated through TCR signaling, includ-
ing AP1 (22), cRel (26), and FOXO1/3 (18). This promoter 
activity is relatively weak, and cell type-specific expression of 
mFoxp3 gene is cooperatively maintained by enhancers located 
in CNS1 and CNS2. TGF-β and IL-2 signaling response ele-
ments are located in the CNS1 and CNS2 regions, respectively 
(28, 31–33). We have identified an enhancer (Enhancer1) in 
the CNS1 region, and Enhancer1 is activated by signaling 
through the TGF-β receptor and TCR via Smad3 and NFAT, 
respectively (28). Subsequently, Xu et  al. (29) have shown 
that AP1 and retinoic acid also regulate the activity of this 
enhancer. Another enhancer (Enhancer 2) is located in CNS2 
and functions as an IL-2/TCR response regulatory region (19, 
31). Foxp3 expression and Treg function are also regulated 
by DNA methylation (34, 35). Indeed, this CNS2 enhancer is 
negatively regulated by DNA methylation through a CpG island 
that is highly methylated in Foxp3− cells, but demethylated in 
Foxp3+ Treg. Several transcription factors activated by TCR 
signaling bind to this enhancer (19, 31, 36), yet as activities of 
these factors are DNA methylation sensitive, it is unclear how 
the highly methylated enhancer becomes activated. Recently, 
we proposed that activated STAT5 generated through TCR/
TGF-β/IL-2 signaling pathways binds to the methylated CNS2, 
so enabling enhancer activity (31). The contribution of CNS3 
in inducing mFoxp3 is distinct from these enhancers. It is 
thought that CNS3 interacting with cRel induces mFoxp3 gene 
expression through chromatin remodeling of the mFoxp3 gene 
locus in nTreg precursor cells (30).
In contrast with murine studies, the regulation of the human 
FOXP3 (hFOXP3) gene remains poorly understood. Although 
the analysis of hFOXP3 gene expression in immune mediated 
diseases may provide clues to clinical relevance, such information 
is also confounded by disease variants and distinctive features of 
individual patients (37). Equally, attempts to stabilize hFOXP3 
expression in adoptive T-cell therapy, for both natural and induced 
Treg, would benefit from simple reporter readouts of FOXP3 gene 
expression both in vivo and in vitro. To address these issues, we 
have generated hFOXP3 expression reporter transgenic mice and 
cell lines using BAC technology. Since BAC clones contain long 
DNA fragments (approximately 200-kb), gene expression from 
BAC DNA in transgenic mice is usually identical to that of the 
endogenous gene. Indeed, to control tissue specific gene expres-
sion of particular proteins (e.g., Cre recombinase), transgenic 
mice carrying the modified BAC DNA (e.g., insertion of the Cre 
recombinase cDNA into the target genes in BAC DNA) have been 
widely generated (38).
The resulting transgenic mouse exhibited AmCyan (hFOXP3) 
expression which was restricted to CD3+CD4+CD25+ cells in 
thymus and spleen, and inducible in naive CD4+ T-cells in a TGF-
β-dependent way. In previous studies (23, 26, 28, 29, 31), we and 
others have characterized mFoxp3 promoter and enhancer activi-
ties using a murine T cell line, EL4 (LAF and B02 sub-clones), 
which expresses mFoxp3 under similar inductive influences as 
those for primary mouse CD4+ T-cells. In order to study hFOXP3 
expression in vitro and to screen for drugs that impact its expres-
sion, we also generated a hFOXP3 reporter system using this cell 
line. Collectively, our data obtained with these reporter systems, 
indicate that the known murine inductive influences also control 
hFOXP3 gene expression. These findings provide some basis for 
screening of drugs that could modulate hFOXP3 expression both 
in vitro and in vivo.
MaTerials anD MeThODs
generation of human FOXP3 Bac 
Transgenic Mice
A human BAC clone containing hFOXP3 gene, RP11-344O14 
was purchased from Life Technologies. The 5′-half of BAC DNA 
was removed by homologous recombination by using RedET 
recombinase (39, 40) (Gene Bridges) with the homologous arm 
encoded in the vector and the BAC DNA located 3′-downstream 
region of the repetitive DNA region (Figure  1A). To replace 
hFOXP3 gene expression with a fluorescent protein, AmCyan 
cDNA (from the first ATG) was inserted just downstream of 
the first ATG of hFOXP3 (the hFOXP3 first ATG was replaced 
by the AmCyan first ATG) by a homologous recombination 
procedure with modifications. BAC transgenic C57BL/6 
mice were generated and bred by the Mouse Genetic Core 
at Cedars-Sinai Medical Center. Experimental protocols using 
the transgenic mice were approved by IACUC at Cedars-Sinai 
Medical Center (#3001&6528).
FigUre 1 | continued
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generation of human and Mouse FoxP3 
expression reporter lines
To generate hFOXP3 expression reporter cell lines, the same 
modified hFOXP3 BAC was used with the addition of a neomycin 
resistance gene (under control of a CMV promoter). This resist-
ance gene was inserted into the vector sequence upstream of the 
5′-end of the BAC DNA. mFoxp3 expression reporter cell lines 
were also generated using the mouse BAC clone RP23-267C15 
(Life Technologies). mFoxp3 expression from this BAC clone was 
replaced by the mCherry fluorescent protein by the same proce-
dure as described for the hFOXP3 BAC modification. The result-
ing hFOXP3/AmCyan and mFoxp3/mCherry modified BAC are 
illustrated in Figures 3A and 4A, respectively. These BAC DNAs 
were transfected into EL4 B02 sub-clone cells by nucleofector 4D, 
and transfectants were selected by culture with G418 for 2 weeks. 
To select AmCyan (hFOXP3) and mCherry (mFoxp3) express-
ing cells, these transfectants were stimulated by plate-coated 
anti-CD3 (5 μg/ml in PBS) and TGF-β (5 ng/ml) for 48 h and 
AmCyan and mCherry positive cells were sorted and cloned by 
limiting dilution. JE6.1 transfectants using the hFOXP3/AmCyan 
BAC construct were also generated by the same strategy as that 
used for generating the EL4 reporter cells shown in Figure S1B in 
Supplementary Material.
analysis of integrated Bac region
Hunan BAC DNA in hFOXP3/AmCyan transgenic mice and 
cell lines were analyzed by PCR using genomic DNA as well as 
DNA sequencing of the PCR products. PCR primer binding 
positions are shown in Figure 2A. Primer sequence used were 
Us4F: CCATTATTTGCCACCTCTTCGTGG, Us4R: AGTTCA 
FigUre 1 | amcyan (hFOXP3) expression in hFOXP3 bacterial artificial chromosome (Bac) transgenic mice. (a) Structure of human BAC DNA 
(RP11-344O14) is illustrated. Relative positions of the exons (boxes), Enhancer1 (En1) in hCNS1, Enhancer2 (En2) in hCNS2, the first ATG of the hFOXP3 gene, and 
the inserted AmCyan gene are indicated. The 3′-end of the repetitive sequence in the BAC DNA is indicated by an arrow. (B) AmCyan (hFOXP3), mFoxp3 (internal 
staining), and CD25 expression in CD3+CD4+, CD3+CD4−, and CD3− splenocytes and thymocytes from AmCyan/FOXP3 transgenic mice (hFOXP3 BAC Tg) and 
wild-type (WT) C57BL/6 mice were analyzed by flow cytometry. (c) AmCyan (hFOXP3) and CD25 expression in TGF-β induced Treg (iTreg) was analyzed by flow 
cytometry. To generate iTreg, CD4+CD25− T cells were isolated from spleen of the hFOXP3/AmCyan transgenic mice (hFOXP3 BAC Tg) or WT C57BL/6 mice WT 
and stimulated with anti-CD3 + anti-CD28 + IL-2 with or without TGF-β for 72 h. (D) Chromatin immuno-precipitation assays were performed with CD4+CD25−, 
nTreg and iTreg (CD4+CD25− T-cells stimulated with anti-CD3 + anti-CD28 + TGF-β for 48 h) enriched population using anti-acetyl histone H4 (AcH4) or control IgG 
and human-specific PCR primers binding to the hFOXP3 promoter, the En1 in CNS1, or the En2 in CNS2. Human specificity of the primers are shown in Figure 2B. 
Data are representative of three (B,c) or four (D) independent experiments (error bars indicate the SD of triplicate samples).
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GACTTGGTCCGGATGGT, Us3F: CAATCGCCCCTTCTTC 
ACCT, Us3R: CCTCTGCGTTTTGTCACACG, Us2F: GCCTT 
ACAAGAGCTCCTGAAGGAAG, Us2R: GGTGCTCCTGTA 
TTGGGTGCATA, Us1F: CCGAAGCTTGCCAATTGCTT, 
Us1R: TGTGACTATTGCTGGGCTGG, hPROF: CGTGATTAT 
CAGCGCACACACTCA, hPROR: CTGGGTACATCCCACTG 
TACCAGA, hCNS1F: GGTTGTCTGGTCATGTCCTTACTCC, 
hCNSR: ATCACACATAGGGCTTGGGGTGAC, hCNS2F: TG 
GTGTCGATGAAGCCCGGC, hCNS2R: CATGGAGATGAT 
CTGTCTGGGGGTAG, hExon11F: GTACACTCAAACAACC 
TCAAAGCTGC, hExon11R: TGCATATGCGTGAGATACACA 
GGTG, Ds1F: ATGGTGGAGATCACCAGCAAGCA, Ds1R: CT 
GGTCGGATTTCGCAGCTCCTA, Ds2F: CTCCTATTCCTTC 
TACCCCAGAAGCT, Ds2R: CAGACAGTGTGATGATAAGA 
GCCTGG, Ds3F: TATTGTGGTGGGCAGCATAGTGGA, 
Ds3R: ACCGATGGAGAAGCCAATGGAGAA, Ds4F: GAAA 
GAAGTAGGCACAGCGGTGAG, Ds4R: GTGGATAAATGACG 
TGCCCATGAG, AmCyanF: ACATCCTGTCCACCGTGTTCA 
TGT, AmCyanR: ATGGTCACGGGCTTCTTGGTCTTGT, 
mEN2F: GAAAGACAGAATCGATAGAACTTGG, and mEN2R: 
AATATGTTTTCCTATCGGGGTCTAC.
cell culture and reagents
EL4 sub-clone B02 cells were cultured in IMDM with 
l-glutamine and 25 mM HEPES (Cellgro) and 5% FBS. Primary 
T-cells were cultured in RPMI 1640 with l-glutamine (Cellgro) 
and 10% FBS. CD4+CD25+ and CD4+CD25− T-cells from spleen 
were isolated using EasySep™ mouse CD4+CD25+ regulatory 
T-cell Isolation kit (STEMCELL). The purity of CD4+CD25+ 
T-cells and CD4+CD25− T-cells was higher than 80%. mFoxp3 
expression was analyzed using a Foxp3 staining kit (eBiosciences). 
To generate iTreg cells, CD4+CD25− T-cells were cultured with 
plate-coated anti-CD3 (KT3, 5 μg/ml in PBS), anti-CD28 (1 μg/
ml), recombinant human TGF-β1 (Peprotech, 5  ng/ml), and 
mouse IL-2 (Peprotech, 20  ng/ml). Pharmacological inhibi-
tors, Smad3 inhibitor (SIS3, EMD Millipore), JNK Inhibitor 
II (SP600125, LC laboratories), CsA (Sigma-Aldrich), STAT5 
inhibitor (Calbiochem, Millipore), JAK inhibitor (R545, Rigel), 
FigUre 2 | structure of hFOXP3 bacterial artificial chromosome (Bac) Dna. (a) Relative position of the hFOXP3 gene is indicated by thick line, positions of 
the hFOXP3 promoter, hCNS1, hCNS2, and the last exon (hExon11) are also indicated. PCR primer binding sites used in B and C are also indicated. (B,c) DNA 
isolated from hFOXP3/AmCyan reporter cells (hFOXP3/EL4), hFOXP3/AmCyan transgenic mouse (hFOXP3/Tg), C57BL/6 mouse, human HeLa cells, and 
RP11-344O14 BAC clone were analyzed by PCR. The PCR products using chromatin immuno-precipitation primers (in B) were analyzed by agarose gel and shown 
in (B). The PCR products using primers binding to indicated positions (a) were analyzed by agarose gel and shown in (c). AmCyan and mCNS2 primers shown in 
(c) are binding to AmCyan gene and mouse CNS2 sequences, respectively. Data are representative of four (B,c) independent experiments.
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and Torin1 (Millipore) were used where indicated. For FACS 
staining, anti-CD3, anti-CD4, anti-CD25, and anti-Foxp3 
(eBioscience) were used.
chromatin immuno-Precipitation (chiP)
Chromatin immuno-precipitation assays were performed using 
freshly isolated CD4+CD25− T-cells, CD4+CD25− T-cells treated 
with anti-CD3 + anti-CD28 + TGF-β, and CD4+CD25+Foxp3+ 
nTreg cells from hFOXP3 BAC transgenic mice, as well as EL4 
transfectants as described previously (28). Briefly, these cells 
were fixed (for 10  min at room temperature in 1% formalde-
hyde, 4.5  mM HEPES pH 8.0, 9  mM NaCl, 0.09  mM EDTA, 
and 0.045 mM EGTA) and sonicated (Bioruptor) in lysis buffer 
(1% SDS, 10  mM EDTA, and 50  mM Tris–HCl pH 8.0) with 
proteinase inhibitor (Sigma-Aldrich P8340). Pre-cleared lysates 
were incubated overnight at 4°C with polyclonal anti-acetyl 
histone H4 (Millipore) or control rabbit IgG (Santa Cruz). DNA 
fragments were isolated from the immuno-precipitated chro-
matin and analyzed by real-time PCR with SsoAdvance SYBR 
supermix (Bio-Rad). PCR primers for ChIP used were hFOXP-
3ProF: CTGGCATTTCCCATCCACACATAGA, hFOXP3ProR: 
TGAGTGTGTGCGCTGATAATCACG, hFOXP3CNS1F: GGT 
TGTCTGGTCATGTCCTTACTCC hFOXP3 CNS1R: ATCAC 
ACATAGGGCTTGGGGTGAC, hFOXP3CNS2F: ACCCAAG 
AAGGGCCAGGTCTTC, and hFOXP3En2R: GCCGGGCTT 
CATCGACACCA.
resUlTs
human FOXP3 (amcyan) expression in 
hFOXP3 Bac Transgenic Mice
To confidently exploit knowledge of foxp3 gene expression for 
therapeutic benefit, we sought to establish whether the human 
6Tsuda et al. Regulation of Human FOXP3 Expression
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gene can be expressed in both transgenic mice and cell lines using 
an hFOXP3 BAC clone (RP11-344O14). To avoid any potential 
disruption of Treg development from an additional functional 
hFOXP3 gene in the transgenic mice, and to provide a sensitive 
reporter of hFOXP3 expression, a fluorescent protein AmCyam 
gene was inserted into the hFOXP3 gene in the BAC DNA by 
homologous recombination, resulting in the BAC construct 
being unable to express hFOXP3 protein (hFOXP3 expression is 
replaced by AmCyan) (Figure 1A). During the BAC DNA modi-
fication process, we found a long repetitive DNA region located in 
the 5′-half of the clone (Figure 1A). Since this repetitive sequence 
interfered with the modification process, we removed the 5′-
half of the BAC DNA sequence. The resulting BAC, therefore, 
contains 52 and 59 kb DNA sequences at the 5′- and 3′-flanking 
regions of the hFOXP3 transcription start site, respectively. To 
replace hFOXP3 expression with AmCyan, cDNA encoding this 
fluorescent protein was inserted just downstream of the first 
ATG of the hFOXP3 gene (the first ATG of the hFOXP3 gene 
was replaced by that of the AmCyan cDNA, resulting no hFOXP3 
protein expression) (Figure 1A). C57BL/6 transgenic mice were 
generated using the modified BAC DNA, and AmCyan (hFOXP3) 
expression was analyzed by FACS.
amcyan (hFOXP3) expression Was 
restricted to cD3+cD4+cD25+ cells and 
TgF-β induced Treg
Expression of both AmCyan and endogenous mFoxp3 was 
detected only within CD3+CD4+ cells (but not in CD3− cells nor 
other CD3+ cells such as CD3+CD8+ cells) and was restricted 
to CD4+CD25+ cells from the thymus and spleen of the BAC 
transgenic mice. No AmCyan expression could be detected in 
wild-type (WT) mice (Figure 1B). This tells us that the devel-
opmental pathway for mouse nTreg, can provide all the cues for 
BAC hFOXP3 expression. However, although cell type expression 
patterns of AmCyan and mFoxp3 were similar, the percentage of 
mFoxp3+ cells was higher than that expressing AmCyan+. Since 
the ratio of AmCyan+ compared to mFoxp3+ cells was similar 
in spleen and thymus (in Spleen, AmCyan+ 6.17% vs. mFoxp3+ 
10.9% and in Thymus, AmCyan+ 1.99% vs. mFoxp3+ 3.11%), 
hFOXP3 induction in tTreg precursor cells appeared to be some-
what less efficient than for the endogenous gene.
To examine the performance of the BAC construct in murine 
iTreg, we examined the effect of TGF-β in regulating hFOXP3 
expression in in  vitro. CD4+CD25− T-cells were isolated from 
spleens of the hFOXP3 BAC transgenic and WT mice, and cul-
tured with anti-CD3 + anti-CD28 + IL-2 with or without TGF-β 
(Figure  1C). Expression of AmCyan (hFOXP3) and mFoxp3 
(internal staining) was observed only in cells cultured with 
TGF-β, indicating that hFOXP3 gene expression is also TGF-β 
dependent. Yet again, however, the percentages of TGF-β-induced 
hFOXP3+ iTreg from the BAC transgenic mice (28.8%) were 
lower than mFoxp3+ iTreg generated from WT (52.0%) and the 
BAC transgenic mice (50.1%). Taken together, these data suggest 
that fundamentally, hFOXP3 and mFoxp3 genes behave similarly 
in the murine inductive conditions, but that hFOXP3 (AmCyan) 
expression is somewhat constrained. This could be due to features 
of the transgenic mice generated with the engineered BAC DNA 
construct or to transcriptional activity of gene expression for 
hFOXP3 being weaker than that for mFoxp3. It is also possible 
that the Foxp3 staining process, in some way, inhibits AmCyan 
intensity. We, therefore, further investigated whether the regula-
tory regions identified for mFoxp3 expression also function for 
the hFOXP3 gene. As shown in previous studies (18–30), mFoxp3 
transcription is regulated by three regulatory regions located in 
the promoter, CNS1 and CNS2. Many histone modifications can 
be used to assess the accessibility of chromatin in these regions 
by ChIP assay using anti-acetyl-histone and anti-methyl-histone 
(e.g., H3K27ac, H3K27me3, H3K9me3, and H4ac). We per-
formed ChIP assays using anti-acetyl histone H4 and human-
specific PCR primer sets to compare with the previous mFoxp3 
ChIP data obtained using the same antibody (28, 31). The relative 
positions of the promoter, human CNS1 (hCNS1), and hCNS2 
are shown in Figure 1A and Figure 2A, and human specificity of 
the primers for ChIP assay was shown in Figure 2B. Histone H4 
molecules in the hFOXP3 promoter (hPro), hCNS1, and hCNS2 
were highly acetylated in both the nTreg and iTreg (CD4+CD25− 
T cells stimulated with anti-CD3 + anti-CD28 + TGF-β for 48 h) 
enriched populations, but not in the control freshly isolated 
CD4+CD25− T-cells (Figure  1D). This pattern was identical to 
that in mFoxp3 gene as previously shown (28, 31). Taken together, 
these data suggest that mFoxp3 and hFOXP3 induction can be 
regulated by similar mechanisms through the promoters, hCNS1 
and hCNS2.
generation of human and Mouse foxp3 
gene expression reporter cells
The data obtained using hFOXP3/AmCyan transgenic mice 
suggested that both human and mouse foxp3 gene expression 
can utilize identical regulatory regions in the corresponding 
genes. To investigate mouse and human foxp3 gene expression 
further, and to establish a screening system for drugs influencing 
hFOXP3 gene expression, we generated a hFOXP3 expression 
reporter cell line using hFOXP3/AmCyan BAC DNA and EL4 
sub-clone B02. As we have previously shown (28, 31), both EL4 
sub-clones LAF and B02 expressed mFoxp3 after stimulation 
with anti-CD3 + anti-CD28 + TGF-β, indicating that mFoxp3 
expression in these sub-clones is induced by TCR activation 
and TGF-β signaling as in TGF-β induced Treg, unlike the 
original EL4 cell line. Furthermore, using these sub-clones, we 
and others have identified diverse transcription factors involved 
in mFoxp3 gene expression (23, 26, 28, 29, 31). Therefore, we 
generated hFOXP3/AmCyan BAC (Figure  3) and mFoxp3/
mCherry BAC (Figure 4) transfectants using EL4 B02 cells, as 
hFOXP3 and mFoxp3 expression reporter systems. To select 
BAC transfectants, the neomycin-resistant gene was inserted at 
the 5′-end of the BAC DNA (Figures  3A and 4A). Although 
BAC transfectants were selected by G418 as neomycin resistant, 
many transfectants might, in principle, have lost the foxp3 gene 
and/or essential transcriptional regulatory regions for FoxP3 
expression during the BAC DNA integration process. To select 
for FoxP3 expressing transfectants, these G418 resistant cells 
were stimulated with anti-CD3 + TGF-β for 48 h and AmCyan 
and mCherry positive cells were sorted and cloned by limiting 
FigUre 3 | generation and characterization of hFOXP3/amcyan expression reporter cells. (a) Structures of hFOXP3/AmCyan bacterial artificial 
chromosome (BAC) DNA are illustrated. Relative positions of hFOXP3 promoter, hCNS1, and hCNS2 are shown. AmCyan gene was inserted in the hFOXP3 gene by 
homologous recombination using the indicated donor fragment with 5′and 3′-homologouse arms and poly(A) additional sequence. Neomycin-resistant gene is 
inserted at the 5′-end of the BAC DNA. (B) hFOXP3/AmCyan reporter cells were stimulated (for 48 h) with no stimuli (Non-stimulated), anti-CD3 + anti-CD28 without 
or with TGF-β, and AmCyan (hFOXP3) expression was analyzed by flow cytometry. (c) hFOXP3/AmCyan reporter cells were stimulated with anti-CD3 + anti-CD28 
and cultured with anti-TGF-β (with indicated concentration). AmCyan expression was analyzed by flow cytometry. (D) Chromatin immuno-precipitation assay was 
performed using anti-acetyl histone H4 (AcH4) or control IgG and non-stimulated (Non) cells, or stimulated cells by anti-CD3 + anti-CD28 without (−) or with (+) 
TGF-β. Human specificity of the used primers binding to the promoter, hCNS1 and hCNS2 are shown in Figure 2B. Data are representative of four (B), three (c), 
or four (D) independent experiments (error bars indicate the SD of triplicate samples). Three (B) and two (c) independent clones were also analyzed.
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FigUre 4 | generation and characterization of mFoxp3/mcherry expression reporter cells. (a) Structures of mFoxp3/mCherry BAC DNA are illustrated. 
mCherry gene was inserted in the mFoxp3 gene by homologous recombination with the similar strategy shown in Figure 3a. (B) mFoxp3/mCherry reporter 
cells were stimulated (for 48 h) with no stimuli (non-stimulated), anti-CD3 + anti-CD28 without or with TGF-β, and mCherry (mFoxp3) expression was analyzed by 
flow cytometry. (c) mFoxp3/mCherry reporter cells were stimulated with anti-CD3 + anti-CD28 and cultured with anti-TGF-β (with indicated concentration). 
mCherry expression was analyzed by flow cytometry. Data are representative of four (B) or three (c) independent experiments. Four (B) independent clones 
were also analyzed.
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dilution. During this cloning step (culturing without stimuli 
for about 2  weeks), stimulated cells reverted to the “resting” 
state and did not express these fluorescent proteins without 
further stimulation.
Since consistent AmCyan (hFOXP3) gene expression in the 
hFOXP3/AmCyan transgenic mice could be detected in appro-
priate cell types, it appears that mouse and human foxp3 genes 
exploit common regulatory mechanisms. However, reporter 
systems using human cell lines would, if available, enable 
identification of any human-specific regulatory mechanisms. 
To this end, we have sought human T-cell lines that regulate 
inducible hFOXP3 expression akin to iTreg. None have been 
described. However, since we can stimulate the human T cell 
line JE6.1 with anti-CD3 and TGF-β (41, 42), we generated 
transfectants using the same hFOXP3/AmCyan BAC construct 
(Figure  3A) with the strategy that had proven successful for 
EL4 B02 cells (Figure S1 in Supplementary Material). However, 
the expression pattern of endogenous hFOXP3 mRNA from 
JE6.1 was unlike iTreg. hFOXP3 mRNA was detected in non-
stimulated cells, yet not significantly upregulated by stimula-
tion (Figure S1A in Supplementary Material). Importantly, 
AmCyan (hFOXP3) expression from the BAC DNA in JE6.1 
transfectants was similar to that of the endogenous hFOXP3 
(Figure S1C in Supplementary Material), but dissimilar to 
iTreg and reporter cells generated using the EL4 B02 line. 
In short, the expression of the foxp3 gene in Treg seems not 
only to be determined by regulatory regions in this gene but 
also by other, as yet, undefined regulatory mechanisms. The 
result suggests although EL4 B02 line is a mouse cell line, it 
remains the best option for a reporter system to date, albeit 
not covering as putative set of human-specific regulatory 
mechanisms.
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TgF-β-Mediated amcyan (hFOXP3) and 
mcherry (mFoxp3) induction in the 
reporter cells
To examine whether expression of AmCyan (hFOXP3) and 
mCherry (mFoxp3) in BAC transfectants was similar to mouse 
primary T-cells, cloned transfectants were re-stimulated by anti-
CD3 + anti-CD28 with or without TGF-β and analyzed by FACS. 
The expression patterns of both AmCyan (hFOXP3) (Figure 3B) 
and mCherry (mFoxp3) (Figure 4B) in these transfectants were 
similar, and induction of both AmCyan and mCherry was TGF-
β dependent, just as in hFOXP3 BAC transgenic mice and WT 
mice (Figure 1C). However, 3 to 8% of AmCyan+ and mCherry+ 
cells were always detected in cultures stimulated with anti-CD3+ 
anti-CD28, but without additional TGF-β (4.5% in Figure  3B 
and 3.7% in Figure  4B). This residual AmCyan and mCherry 
induction was, however, inhibitable by addition of anti-TGF-β 
(Figures  3C and 4C), implicating other sources of TGF-β as 
responsible (e.g., TGF-β expressed by EL4 cells themselves and/
or bovine TGF-β in FBS).
We, next, examined whether the three regulatory regions 
identified in the hFOXP3/AmCyan transgenic mice (promoter, 
hCNS1 and hCNS2) (Figure 1D) and WT mice (28, 31) are also 
involved in induction of hFOXP3 expression in the EL4 reporter 
cells. We assessed the “open chromatin status” of these regulatory 
regions by ChIP assay (Figure 3D) using anti-acetyl histone H4 
and the human-specific PCR primers (Figures 2A,B). As with 
the hFOXP3/AmCyan transgenic mice (Figure  1D), histone 
H4 molecules in the hPro, hCNS1, and hCNS2 were highly 
acetylated only in anti-CD3 + anti-CD28 + TGF-β stimulated 
cells, suggesting that hFOXP3 expression in the EL4 reporter 
cells could also be induced through these three regulatory 
regions with TCR and TGF-β signaling. These data suggest that 
the EL4 reporter system should be useful for further studies of 
hFOXP3 expression and identification of potential therapeutics 
in modulating hFOXP3 expression.
The regulatory regions controlling cell 
Type-specific hFOXP3 expression in Treg 
are located within the 110-kb Bac Dna 
sequence
The regulation of hFOXP3/AmCyan expression in the reporter 
transgenic mice and transfectants appeared similar to that 
previously seen in mouse primary T-cells. This indicates that 
the human BAC DNA in both transgenic mice and transfectants 
contains all relevant regulatory regions required for Treg specific 
hFOXP3 gene expression in murine cells. We analyzed the inte-
grated area of the hFOXP3 BAC DNA in the transgenic mice and 
transfectants by PCR using human-specific primer sets (relative 
positions of these primer binding sites are shown in Figure 2A). 
As shown in Figure 2C, strong amplification bands were detected 
with the human-specific PCR primer sets using DNA from HeLa 
cells and the BAC clone (RP11-344O14) but not using DNA from 
WT C57BL/6 mice (only weak non-specific bands were detected 
with some of these primers). In the transgenic mice, a strong PCR 
band was detected with the Us3 primer set (binding to −40 kb 
from the transcription start site of the hFOXP3 gene), but not 
with the Us4 primer (binding to −51 kb), implicating the 5′-end 
of the hFOXP3 BAC DNA located between −51 and −40  kb 
(Figures 2A,C). Since the neomycin resistant gene is located at 
the 5′-end of the hFOXP3 BAC DNA (Figure 3A), the hFOXP3/
AmCyan EL4 transfectant contains the 5′-end of the BAC DNA, 
and indeed, a strong 5′-band was also detected with the most 
5′-PCR primer set (Us4) (Figures 2A,C). In both the transgenic 
mice and the transfectants, strong PCR bands were detected with 
the most 3′-PCR primer set, Ds4, indicating that both 3′-ends of 
the integrated DNA are located near the 3′-end of the BAC DNA 
(Figure  2C). Taken together with the results of Treg-specific 
hFOXP3/AmCyan gene expression in the transgenic mice, our 
data suggests that the regulatory regions required to maintain 
Treg-specific hFOXP3 gene expression are located within the 
110-kb (−51 to +59 kb) DNA sequence area shown in Figure 2A.
Transcription Factors involved in hFOXP3 
gene expression
We have previously shown that NF-κB cRel (in promoter) (26), 
Smad3 (in CNS1) (28), NFAT (in CNS1) (28), AP1 (in CNS2) 
(31), and STAT5 (in CNS2) (31) cooperate to regulate mFoxp3 
gene expression, and that pharmacological inhibitors of the acti-
vation pathways for these transcription factors blocked mFoxp3 
gene expression. In order to provide a proof of principle test 
that our hFOXP3 construct might serve as a tool to test drugs 
for induction or repression of Foxp3 transcription, we examined 
the contribution of these transcription factors in regulating 
hFOXP3 gene expression. To this end, we used these same 
inhibitors in the context of the hFOXP3/AmCyan expression 
system (Figure 5). mFoxp3 expression was also analyzed using 
the mFoxp3/mCherry expression system as a control. Similar to 
mCherry (mFoxp3) expression, AmCyan (hFOXP3) expression 
was blocked by the inhibitors of these transcription factors. Taken 
together with ChIP data shown in Figures  1D and 3D, these 
findings suggest that hFOXP3 gene expression is also regulated 
by the same transcription factors through the promoter, hCNS1 
and hCNS2.
Since downmodulation of Foxp3 expression by inhibitors for 
NFAT, Smad3, AP1, and STAT5 has previously been described in 
primary iTreg (28, 29, 31), the reporter cells seem useful for iden-
tifying some drugs that can control hFOXP3 gene expression in 
these cells and primary T cells. To further support the potential of 
this system for identifying drugs able to influence hFOXP3 gene 
expression, we assessed a newly synthesized JAK inhibitor (R545) 
(43). Since mouse and human foxp3 gene expression is regulated 
by STAT5, the JAK inhibitor would be expected to downmodulate 
gene expression through blocking phosphorylation of STAT5. 
Indeed, expression of both foxp3 genes is strongly inhibited by 
R545, suggesting that these reporter systems hold promise for 
screening drugs modulating hFOXP3 expression.
hFOXP3 expression is enhanced in the 
reporter cells by Treatment with the 
mTOr inhibitor, Torin1
Next, we sought evidence for drug-induced enhancement of 
hFOXP3 expression using this reporter system. Since Foxp3 
FigUre 5 | inhibition of amcyan (hFOXP3) and mcherry (mFoxp3) expression. mFoxp3/mCherry or hFOXP3/AmCyan reporter cells were cultured with 
different concentrations of the indicated transcription factor inhibitors, NAI (NF-κB activation inhibitor), SIS3 (Smad3 inhibitor), CsA (NFAT inhibitor), JNK inhibitor II 
(AP1 inhibitor), STAT5 inhibitor, and R545 (new JAK inhibitor) for 48 h. mCherry (mFoxp3) or AmCyan (hFOXP3) expression was analyzed by flow cytometry and 
relative expression levels are shown. Data are representative of three independent experiments (error bars indicate the SD of triplicate samples).
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expression is inhibited by the mTOR signaling pathway antago-
nizing the function of Smad3, Foxo1, and Foxo3 (44, 45), we 
examined the effectiveness of an inhibitor (Torin1) (44, 46, 47) of 
mTORC1 and mTORC2 using the stimulated (anti-CD3 + anti-
CD28 + 5 ng/ml TGF-β) hFOXP3/AmCyan reporter cells with 
different concentrations of Torin1 (0–100  nM) (Figure  6A). 
AmCyan expression was induced in 40% of the reporter cells 
without Torin1, and increased with Torin1 in a dose-dependent 
manner. Since mTORC1 inhibits TGF-β-mediated Smad3 activity, 
the effectiveness of Torin1 (100 nM) was assessed using different 
dose of TGF-β (0–5 ng/ml). As shown in Figure 6B, using 100 nM 
of Torin1, AmCyan+ cells could be detected following exposure 
to low doses of TGF-β, and numbers increased substantially with 
higher doses of TGF-β. Although 39.9% of Torin1 treated cells 
and 7.65% of non-treated cells were detected as AmCyan+ cells 
without addition of TGF-β, induction of these cells was inhibited, 
as before, by anti-TGF-β (Figure 6C), indicating enhancement of 
hFOXP3 expression is completely TGF-β dependent.
DiscUssiOn
Research on Foxp3 gene expression has contributed significantly 
to our understanding of the biology of Treg. To date, most such 
studies have been conducted in mice facilitated through the avail-
ability of genetically modified mice and disease models. However, 
recent studies have suggested that the mouse and human foxp3 
genes may be regulated differently possibly minimizing the appli-
cability of the rapidly accumulating murine data. For example, 
unlike mouse T-cells, hFOXP3 expression in human T-cells can 
be induced without the apparent need for TGF-β. It is not clear 
what these disparities are due to, and has left a question mark 
around the mouse data. In an attempt to clarify the situation, we 
transferred the hFOXP3 gene with regulatory elements to mouse 
by creating transgenic mice using human FOXP3 BAC reporter 
constructs. We observed that the cellular distribution and induc-
ibility of the reporter AmCyan (hFOXP3) expression was similar 
to mFoxp3 expression in these BAC transgenic mice. This suggest 
that, at least in part, mouse and human foxp3 gene expression is 
regulated by the common mechanisms and the hFOXP3 expres-
sion reporter system can be utilized for studying both funda-
mental and clinically applicable mechanisms. The major impact 
of this reporter system is that (i) we can use the transgenic mice 
to study hFOXP3 gene expression under defined experimental 
conditions in vivo and (ii) we can assess the effects of potential 
disease modifying drugs for their impact on hFOXP3 expression 
in the reporter transgenic mice, and in mice derived by crossing 
the reporter transgenic mice to disease-prone animals. As shown 
in Figures  5 and 6, EL4/hFOXP3/AmCyan system is useful to 
screen potential drugs to modulate hFOXP3 gene expression. The 
identified potential drugs can be analyzed using the hFOXP3/
AmCyan transgenic mice (in vitro and in vivo), and then, in due 
course, their efficacy confirmed on human Treg. With the trans-
genic mice data obtained in the more homogenous cell popula-
tion, we may be able to avoid artifacts seen in the heterogeneous 
populations of human Treg.
The disadvantage of this transgenic mouse reporter system is 
that it is not suitable as a first-line simple screen for potential 
drugs that might control hFOXP3 expression and, by implication, 
Treg activity. To resolve this problem, we generated a hFOXP3 
expression reporter cell line. The advantage of this is that we can 
provide large numbers of cells for drug screening, and can exploit 
transfection-based methods to study hFOXP3 gene expression. 
Its disadvantage is that since EL4 B02 is of murine origin, we can-
not identify drugs targeting human-specific mechanisms, if such 
exist. However, all our data obtained using hFOXP3/AmCyan 
reporter transgenic mice and cell lines indicate that a substantive 
degree of hFOXP3 gene expression can be regulated by mecha-
nisms similar to those influencing mFoxp3 gene expression, as 
might be predicted from the finding that the foxp3 gene structures 
are highly conserved in all mammals (48).
mFoxp3 gene expression is regulated by a promoter and two 
enhancers located in CNS1 and CNS2, and histone H4 molecules 
in these regions in Foxp3 expressing cells are highly acetylated, 
indicating open chromatin status in these regions. Importantly, 
ChIP data suggest that these regions in the hFOXP3 gene are also 
opened in nTreg and iTreg in the reporter systems, suggesting 
that these regions also function as promoter and enhancers in 
humans. NF-κB cRel bind to the promoter, Smad3, NFAT, and 
AP1 bind to CNS1, and STAT5 bind to CNS2 in the mFoxp3 
gene. Inhibitors of these transcription factors strongly down-
modulated hFOXP3 gene expression. Taken together, these 
findings suggest that hFOXP3 gene expression is also regulated 
by these same transcription factors through these same regula-
tory regions. A deeper future analysis of chromatin regulation 
with the hFOXP3 transgene by analysis of histone marks, such 
as H3K27ac, H3K27me3 and H3K4, and K9 modification, will 
allow detailed comparison of the transgene regulation with 
primary human T-cells.
As shown in Figure  1C, only half of CD4+ primary T-cells 
induced mFoxp3 after stimulation with TGF-β. First, we thought 
that the partial induction of mFoxp3 gene expression was caused 
by heterogeneity of CD4+ T-cells (e.g., only half of CD4+ T-cells 
can be developed to Treg precursor cells). However, clonal experi-
ments using the FoxP3 expression reporter cells suggested the 
presence of inhibitory mechanisms operating in the negative 
cells. AmCyan (hFOXP3) and mCherry (mFoxp3) expression 
reporter cell lines were cloned by limiting dilution, to ensure 
that we only studied pure clones. Despite this, only 30–42% of 
the cloned cells induced AmCyan and mCherry (Figures  3B 
and 4B). This suggests that hFOXP3 and mFoxp3 induction are 
somehow constrained in the majority of the cells, even though 
all cells have same genetic background and received the same 
TCR/TGF-β signaling. Since an mTOR inhibitor enhanced the 
numbers of cells induced, and their expression levels, one of the 
constraining mechanisms may be through the mTOR signaling 
pathway. Alternatively, foxp3 gene expression in the negative cells 
might be blocked by some epigenetic modification such as DNA 
methylation. In the hFOXP3/AmCyan BAC transgenic mice, 
endogenous mFoxp3+ cells were more numerous than AmCyan+ 
cells. This difference may have been due to the additional tech-
nical processing required for mFoxp3 internal staining. Future 
crosses of the hFOXP3 BAC transgenics with mFoxp3-IRES-GFP 
mice may help to clarify this issue. Alternatively, it is possible 
that mFoxp3+AmCyam− cells do exist and are a consequence of 
FigUre 6 | enhancement of amcyan (hFOXP3) expression by Torin1. AmCyan+ cells were analyzed by flow cytometry, and percentages of positive cells and 
mean fluorescence intensity are indicated. (a) hFOXP3/AmCyan reporter cells were cultured with no stimuli (non-stimulation) or with anti-CD3 + anti-CD28 
(Anti-CD3 + Anti-CD28). AmCyam/hFOXP3 reporter cells were also stimulated by anti-CD3 + anti-CD28 + TGF-β (5 ng/ml) with indicated concentrations (0–100 nM) 
of Torin1 for 48 h. (B) hFOXP3/AmCyan reporter cells were stimulated by anti-CD3 + anti-CD28 without or with (100nM) Torin1 with indicated concentrations of 
TGF-β. (c) hFOXP3/AmCyan reporter cells were cultured with no stimuli (non-stimulation) or with anti-CD3 + anti-CD28 for 48 h. Torin1 and/or anti-TGF-β were 
added into the culture with indicated concentration. Data are representative of four (a), four (B), or three (c) independent experiments.
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other epigenetic influences selectively affecting the hFOXP3 BAC 
gene. Any such human FOXP3 specific regulatory mechanisms 
could, in due course be identified by detailed analysis of DNA 
methylation and histone modifications.
As shown here, the fundamental regulatory mechanisms of 
mouse and human foxp3 gene expression seem to be similar. 
However, induction of hFOXP3 (AmCyan) was always less than 
that of mFoxp3 in the AmCyan/hFOXP3 expression reporter 
transgenic mice. This feature may be due to the integrated position 
of the BAC DNA, and/or unidentified human or mouse specific 
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trol the foxp3 gene expression. Alternatively, different expression 
levels may be controlled by human or mouse specific epigenetic 
regulatory mechanisms. Overall, however, the hFOXP3/AmCyan 
expression reporter system appears useful in identifying physi-
ological factors and drugs influential to hFOXP3 expression, and 
may have utility in determining why Treg may, sometimes, fail to 
prevent immunopathology in diverse disease models.
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